The European Federation of Pharmaceutical Industries and Associations said that proposals by the European Medicines Agency to make clinical trial data public could compromise sensitive proprietary research and place their companies at a competitive disadvantage. The EMA draft plan, scheduled to go into effect by Jan. 1, is open for three months of comments. The federation says it is preparing its own alternative for publishing trial results.

Related Summaries